GlassScriptPhysician profile
Joshua Buck
NPI 1205357977
$19,064.50
in general payments reported to CMS, 2019-2025
72 companies · $4,108 in 2025
The $4,108 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,890 · 2022: $3,495 · 2023: $4,527 · 2024: $5,044 · 2025: $4,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $1,363 · Education: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,208.78 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $1,107.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,512.10 | 2021-2025 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $1,378.17 | 2021-2025 | Tagrisso, Enhertu, Lynparza |
| Janssen Biotech, INC. | $1,029.58 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $1,014.67 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $793.04 | 2021-2025 | Opdivo, Krazati, Opdualag |
| Incyte Corporation | $706.27 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $703.48 | 2021-2025 | Padcev, Vyloy |
| Pfizer INC. | $697.17 | 2022-2025 | |
| Daiichi Sankyo INC. | $640.87 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $614.15 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Aveo Pharmaceuticals, INC. | $553.13 | 2021-2025 | Fotivda |
| Amgen INC. | $487.94 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Gilead Sciences, INC. | $484.50 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $465.56 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $445.94 | 2021-2025 | Tecentriq, Phesgo, Perjeta |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $437.72 | 2022-2023 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $404.71 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $391.97 | 2021-2025 | |
| Genzyme Corporation | $371.46 | 2022-2025 | |
| Eisai INC. | $327.23 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.79 | 2022-2025 | Ninlaro, Alunbrig, Exkivity |
| Sanofi-Aventis U.S. LLC | $299.50 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $276.59 | 2021-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $251.23 | 2021-2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $189.71 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $186.32 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $185.82 | 2021-2025 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $178.08 | 2022-2025 | Bavencio |
| Puma Biotechnology, INC. | $160.68 | 2022-2025 | |
| Tersera Therapeutics LLC | $155.11 | 2021-2025 | Zoladex, Xermelo |
| Rigel Pharmaceuticals, INC. | $146.13 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $134.02 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $131.84 | 2022-2024 | Brukinsa |
| Genmab U.S., INC. | $117.36 | 2023-2025 | Epkinly |
| Array Biopharma INC | $112.84 | 2023-2025 | Xalkori, Mektovi, Braftovi |
| Novo Nordisk INC | $111.53 | 2021 | |
| Deciphera Pharmaceuticals INC. | $108.01 | 2022-2025 | Qinlock, Romvimza |
| Biohaven Pharmaceuticals, INC. | $101.81 | 2021 | |
| Karyopharm Therapeutics INC. | $99.79 | 2021-2025 | Xpovio |
| Beone Medicines USA, INC. | $98.44 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.27 | 2021-2024 | Gilotrif |
| Myriad Genetic Laboratories, INC. | $89.97 | 2022-2024 | Precisetumor, Myrisk |
| Morphosys, US INC. | $87.76 | 2022-2023 | Monjuvi |
| G1 Therapeutics, INC. | $72.94 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $66.16 | 2023 | Krazati |
| Caris Mpi, INC. | $59.92 | 2025 | Mi Cancer Seek |
| Geron Corporation | $57.83 | 2025 | Rytelo |
| Kite Pharma, INC. | $55.54 | 2023-2025 | Yescarta |
| Taiho Oncology, INC. | $55.45 | 2022-2025 | |
| Pharmaessentia USA Corporation | $50.27 | 2024-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $44.70 | 2022-2025 | |
| Iovance Biotherapeutics, INC. | $43.88 | 2025 | Amtagvi |
| Epizyme, INC. | $40.73 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $40.58 | 2023-2025 | Empaveli |
| Kyowa Kirin, INC. | $37.31 | 2022-2024 | Poteligeo |
| Sobi, INC | $33.42 | 2022-2023 | |
| Dexcom, INC. | $32.83 | 2021 | |
| Agios Pharmaceuticals, INC. | $31.43 | 2024 | Pyrukynd |
| Celltrion USA INC. | $28.64 | 2025 | Vegzelma |
| Foundation Medicine, INC. | $26.76 | 2023 | |
| Alnylam Pharmaceuticals INC. | $26.36 | 2025 | Givlaari |
| Acceleron Pharma, INC. | $26.27 | 2021 | |
| Legend Biotech USA INC. | $21.34 | 2025 | Carvykti |
| Esperion Therapeutics, INC. | $20.03 | 2021 | |
| Verity Pharmaceuticals INC. | $18.43 | 2023 | Trelstar |
| Servier Pharmaceuticals LLC | $17.67 | 2022 | |
| Fennec Pharmaceuticals, INC. | $17.37 | 2025 | Fyarro |
| Stemline Therapeutics INC. | $16.09 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.24 | 2024 | |
| Pharmacosmos Therapeutics INC. | $12.84 | 2023 | Monoferric |
| Mylan Specialty L.P. | $12.62 | 2021 | |
| Secura Bio, INC. | $6.59 | 2022 |
Drugs and devices associated with these payments
Kisqali $1,721Keytruda $633Fotivda $444Enhertu $422Reblozyl $374Padcev $352Imbruvica $300Darzalex $297Lynparza $274Opdivo $274Epkinly $259Jakafi $258Pluvicto $246Sarclisa $240Tagrisso $234Tukysa $212Ibrance $209Tecvayli $208Libtayo $206Lenvima $191Xtandi $190Adcetris $184Trodelvy $178Krazati $173Brukinsa $162Ninlaro $160Jaypirca $159Verzenio $159Talvey $156Monjuvi $156Ojjaara $151Injectafer $144Erleada $141Xofigo $134Nubeqa $134Ultomiris $132Talzenna $131Orgovyx $129Elitek $129Venclexta $128Elrexfio $123Onivyde $115Tecentriq $113Fabhalta $110Zoladex $101Retevmo $96.55Inlyta $92.81Xalkori $91.89Lutathera $91.23Lorbrena $91.04Braftovi $91.04Mektovi $91.04Phesgo $87.51Perjeta $87.51Qinlock $86.04Calquence $82.89Bavencio $82.83Imfinzi $80.91Comirnaty $78.45Vyloy $77.63Cabometyx $75.65Rezlidhia $73.96Tavalisse $73.96Opdualag $71.75Pemazyre $69.51Vectibix $68.19Nplate $68.19Xgeva $68.19Enjaymo $65.61Nerlynx $65.51Romvimza $65.35Jemperli $60.00Mi Cancer Seek $59.92Rytelo $57.83Precisetumor $56.76Yescarta $55.54Zynyz $54.94Xpovio $51.82Cablivi $51.11Paxlovid $50.74Besremi $50.27Scemblix $48.69Promacta $48.60Welireg $48.24Gavreto $47.08Kyprolis $45.76Keytruda Qlex $44.78Rybrevant $44.26Amtagvi $43.88Stivarga $43.60Alecensa $41.39Balversa $40.85Akeega $40.85Gilotrif $40.73Empaveli $40.58Zejula $35.43Lunsumio $34.66Columvi $34.66Polivy $34.66Blincyto $33.78
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.